Melincoff Gwen A
SEC insider (Form 3/4/5 filer). CIK 0001614890. Director at Protalix BioTherapeutics, Inc. (PLX) and 2 other issuers. 5 reported Form 4/5 transactions since Sep 2024; latest on Sep 3, 2026. Located in CARMIEL.
Companies Melincoff Gwen A has filed insider reports for
- Protalix BioTherapeutics, Inc. (PLX): Director
- Gain Therapeutics, Inc. (GANX): Director
- Chemomab Therapeutics Ltd. (CMMB): Director
Melincoff Gwen A
CIK: 0001614890
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
AwardDirectStock Options (Right to Buy)
17K shares- - Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
AwardDirectRestricted Stock Units
8.5K shares- - Jul 15, 2026GANX
Gain Therapeutics, Inc.
AwardDirectStock Option (right to buy)
25K shares- - Sep 3, 2025PLX
Protalix BioTherapeutics, Inc.
AwardIndirect7.5K shares- - Jun 24, 2025GANX
Gain Therapeutics, Inc.
AwardDirectStock Option (right to buy)
15K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 3, 2026 |  PLX Protalix BioTherapeutics, Inc. | Award Stock Options (Right to Buy) | 17,000 | - | - | Direct |
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | Award Restricted Stock Units | 8,500 | - | - | Direct |
| Jul 15, 2026 |  GANX Gain Therapeutics, Inc. | Award Stock Option (right to buy) | 25,000 | - | - | Direct |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | Award | 7,500 | - | - | Indirect |
| Jun 24, 2025 | GANX Gain Therapeutics, Inc. | Award Stock Option (right to buy) | 15,000 | - | - | Direct |
1-5 of 5 transactions